Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS mystery: do some relapses hide from MRI scans?

NCT ID NCT07545889

Knowledge-focused Sponsor: University Hospital, Strasbourg, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether people with relapsing-remitting multiple sclerosis (RRMS) can have a relapse—new or worsening symptoms—without any visible inflammation on an MRI scan. Researchers will follow 136 adults who are having a suspected relapse, performing early brain and spinal MRIs to check for active lesions. The goal is to better understand these 'invisible' relapses, improve diagnosis, and avoid unnecessary treatments. Participants will also have follow-up visits at 6 months to track their recovery and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 136 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult aged 18 to 70 years. * Relapsing-Remitting Multiple Sclerosis according to the McDonald 2024 criteria. * Patient receiving disease-modifying therapy (DMT) for multiple sclerosis. * Most recent EDSS score between 0 and 7.0, dating back less than 1 year. * Patient presenting with a neurological exacerbation lasting more than 24 hours and less than 7 days (excluding fatigue and pain alone). * Patient capable of understanding the objectives and risks associated with the study and who has provided informed consent. * Patient affiliated with or a beneficiary of a social security health insurance scheme. Exclusion Criteria: * Primary progressive or secondary progressive multiple sclerosis. * Diagnosis of chronic psychotic disorder. * Infection within the past week. * Body temperature \> 38.5°C at V0 (baseline visit). * Corticosteroid bolus or plasma exchange in the month preceding inclusion. * Chronic treatment with corticosteroids or immunosuppressants for another pathology. * Contraindication to MRI or gadolinium. * Uncontrolled cardiac, renal, or hepatic pathology. * Patient participating in another interventional study or still within an exclusion period. * Pregnant or breastfeeding woman. * Severe claustrophobia. * Patient deprived of liberty (e.g., incarcerated).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

conversion disorder multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis Multiple sclerosis (MS) - relapsing-remitting RRMS

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Dijon Bourgogne

    Dijon, 21079, France

  • CHU de Nancy

    Nancy, 54035, France

  • Centre Hospitalier de Haguenau

    Haguenau, 67504, France

  • Chr Metz-Thionville

    Metz, 57085, France

  • Chu Reims

    Reims, 51092, France

  • Grpe Hosp Region Mulhouse & Sud Alsace

    Mulhouse, 68051, France

  • Hospices Civils de Colmar

    Colmar, 68024, France

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67098, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.